<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treosulfan (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treosulfan (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Treosulfan (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="134626" href="/d/html/134626.html" rel="external">see "Treosulfan (United States: Not available): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="134941" href="/d/html/134941.html" rel="external">see "Treosulfan (United States: Not available): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F56621600"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Trecondyv</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F49334598"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent</li></ul></div>
<div class="block doa drugH1Div" id="F49334691"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Nausea and vomiting may commonly occur; consider prophylactic antiemetics to prevent nausea and vomiting. Consider prophylactic or empiric anti-infective treatment (bacterial, viral, fungal).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd4e4060-8502-457f-94ab-b0b55ba44455">Hematopoietic stem cell conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell conditioning regimen: IV: </b>10 g/m<sup>2</sup>/day for 3 days on days −4, −3, and −2 prior to stem cell infusion (total dose/course is 30 g/m<sup>2</sup>) (in combination with fludarabine), followed by stem cell infusion on day 0 (Beelen 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> A missed dose would increase the risk of primary graft failure.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992550"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50989817"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block dot drugH1Div" id="F49334695"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplantation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hematologic toxicity:</b></i>Administer growth factors (G-CSF, GM-CSF), platelet, and/or red blood cell support as clinically indicated.</p></div>
<div class="block doe drugH1Div" id="F49334692"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F56526052"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134941" href="/d/html/134941.html" rel="external">see "Treosulfan (United States: Not available): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not available in the United States. Dose, frequency, number of doses, and/or start date may vary by protocol. Refer to individual protocols. Dosing presented as g/m<sup>2</sup>; use caution. Nausea and vomiting may commonly occur; consider prophylactic antiemetics to prevent nausea and vomiting.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1398fde3-f84a-44a8-b632-980cea80ca78">Hematopoietic stem cell transplantation conditioning regimen, hematologic malignancies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplantation (allogeneic) conditioning regimen, hematologic malignancies:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Other conditioning regimens (ie, total body irradiation-based regimens) are preferred over chemoconditioning for children ≥4 years and adolescents with acute lymphoblastic leukemia receiving allogeneic stem cell transplantation (Peters 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Canadian labeling: </i>Acute myeloid leukemia, myelodysplastic syndrome:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 10 g/m<sup>2</sup>/dose once daily for 3 days on days −4, −3, and −2 prior to stem cell infusion (in combination with fludarabine) (Trecondyv Canadian product labeling 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>European labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Limited data available (Kalwak 2020; Nemecek 2018; Trecondi European Medicines Agency 2019):</p>
<p style="text-indent:-2em;margin-left:8em;">BSA ≤0.5 m<sup>2</sup>: IV: 10 g/m<sup>2</sup>/dose once daily for 3 days on days −6, −5, and −4 prior to stem cell infusion (in combination with fludarabine ± thiotepa).</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &gt;0.5 to ≤1 m<sup>2</sup>: IV: 12 g/m<sup>2</sup>/dose once daily for 3 days on days −6, −5, and −4 prior to stem cell infusion (in combination with fludarabine ± thiotepa).</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &gt;1 m<sup>2</sup>: IV:14 g/m<sup>2</sup>/dose once daily for 3 days on days −6, −5, and −4 prior to stem cell infusion (in combination with fludarabine ± thiotepa).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b27185d8-4a62-4590-8617-3dab717a14d9">Hematopoietic stem cell transplantation conditioning regimen, nonmalignancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplantation (allogeneic) conditioning regimen, nonmalignancy (eg, primary immune deficiency): Note:</b> Various regimens have been described (Chiesa 2020; Morillo-Gutierrez 2020; Slatter 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≤3 months: IV: 10 g/m<sup>2</sup>/dose once daily for 3 days on days −7, −6, and −5 prior to stem cell infusion (in combination with fludarabine and either alemtuzumab or anti-thymocyte globulin) (Chiesa 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 to 12 months: IV: 12 g/m<sup>2</sup>/dose once daily for 3 doses administered on 3 consecutive days (in combination with fludarabine and either alemtuzumab or anti-thymocyte globulin); reported days of treosulfan doses prior to stem cell infusion varied; one trial reported administration on days −7, −6, and −5 (Chiesa 2020) and a retrospective report described administration on days −6, −5, and −4 in patients with chronic granulomatous disease (Morillo-Gutierrez 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 14 g/m<sup>2</sup>/dose once daily for 3 doses administered on 3 consecutive days (in combination with fludarabine and either alemtuzumab or anti-thymocyte globulin); reported days of treosulfan doses prior to stem cell infusion varied; one trial reported administration on days −7, −6, and −5 (Chiesa 2020) and a retrospective report described administration on days −6, −5, and −4 in patients with chronic granulomatous disease (Morillo-Gutierrez 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56526073"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block dohp drugH1Div" id="F56526074"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F49039482"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for combination therapy in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (14%), peripheral edema (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, and adults: 11% to 17%), constipation (12%), diarrhea (children and adolescents: 35%; adults: 16%; grade 3/4: 2%), nausea (children and adolescents: 28%; adults: 33%; grade 3/4: 3%), stomatitis (children and adolescents: 67%; adults: 38%; grade 3/4: 6%), vomiting (children and adolescents: 42%; adults: 22%; grade 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (children and adolescents: 26%), increased serum alanine aminotransferase (children, adolescents, and adults: 9% to 11%), increased serum bilirubin (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (children, adolescents, and adults: 12% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (12%), headache (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (15%), ostealgia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children, adolescents, and adults: 13% to 34%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (children and adolescents: 10%), pruritus (children, adolescents, and adults: 6% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (5%), increased gamma-glutamyl transferase (7%), weight gain (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (7%), dizziness (6%), limb pain (9%), pain (6%), vertigo (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (5%), epistaxis (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all populations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, capillary leak syndrome, cardiac arrhythmia (including atrial fibrillation, sinoatrial nodal rhythm disorder), edema, embolism, flushing, heart failure, pericardial effusion, septic shock, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption, bullous dermatitis, dermal ulcer, dermatitis, diaper rash, erythema multiforme, erythema of skin (including scrotal erythema), exfoliative dermatitis, hyperhidrosis, palmar plantar erythrodysesthesia syndrome, skin hyperpigmentation, skin necrosis, skin rash, skin pain, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis, alkalosis, electrolyte disorder, hyperglycemia, impaired glucose tolerance/prediabetes, increased lactate dehydrogenase, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension, dyspepsia, dysphagia, esophageal pain, esophagitis, gastritis, gastrointestinal hemorrhage, gastrointestinal pain, hiccups, mouth pain, mouth ulcer, neutropenic enterocolitis, proctitis, proctocolitis (anal inflammation), xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (noninfective), dysuria, hematuria, hemorrhagic cystitis, urinary tract pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased, hematoma, hemorrhage, oral hemorrhage, second primary malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic sinusoidal obstruction syndrome, hepatic failure, hepatomegaly, increased serum alkaline phosphatase, liver pain</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, confusion, encephalopathy, extrapyramidal reaction, insomnia, intracranial hemorrhage, myasthenia, noncardiac chest pain, paresthesia, peripheral sensory neuropathy, sensation of cold, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hemorrhage, dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, increased serum creatinine, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, hypoxia, laryngeal edema, oropharyngeal pain, pharyngeal edema, pharyngolaryngeal pain, pleural effusion, pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Seizure (children)</p></div>
<div class="block coi drugH1Div" id="F49334603"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to treosulfan or any component of the formulation; active non-controlled infectious disease; severe concomitant cardiac, lung, liver, or renal impairment; Fanconi anemia and other DNA breakage repair disorders; pregnancy; administration of live vaccine</p></div>
<div class="block war drugH1Div" id="F49334604"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">Bone marrow suppression: Treosulfan causes severe and prolonged myelosuppression. Hematopoietic stem cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. Profound myelosuppression with pancytopenia is the desired effect of treosulfan-based conditioning treatment, occurring in all patients. The risk of infection is increased during severe neutropenia. The median duration of neutropenia is 14 to 17.5 days in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular toxicity: Treosulfan-based conditioning is associated with cardiac arrhythmias (eg, atrial fibrillation, sinus arrhythmia) and rare cardiac failure. Treatment-emergent serious cardiac adverse events (left ventricular systolic dysfunction, myocardial infarction, paroxysmal atrial tachycardia, right ventricular dysfunction) have been observed, although may not be attributed to treosulfan. Safety and efficacy have not been established in patients with severe cardiac impairment and left ventricular ejection fraction &lt;40%; these patients were excluded from the clinical study.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: An increased incidence of skin disorders (eg, rash, dermatitis) was observed when patients received sodium bicarbonate–containing hydration in the course of treosulfan infusion, which may accelerate the pH-dependent formation of alkylating epoxides. Omit skin creams on the days of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Treosulfan is an irritant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicities: Oral mucositis (including severe events) commonly occurs with treosulfan-based transplant conditioning regimen. Mucositis prophylaxis (eg, topical antimicrobials, barrier protectants, cryotherapy, adequate oral hygiene) is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Graft-versus-host disease: Allogeneic hematopoietic stem cell transplantation has been commonly associated with graft-versus-host disease (acute and chronic).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Epistaxis has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Increases in transaminases, bilirubin, gamma-glutamyl transferase, and alkaline phosphatase are commonly observed with treosulfan-based conditioning therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic toxicity: Treosulfan may cause headache or dizziness. Treatment-emergent serious adverse events such as intracranial hemorrhage and/or syncope have been reported. A case of encephalitis infection and intracranial hemorrhage (as a complication of sepsis) was reported. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Dyspnea has occurred with treosulfan. Treatment-emergent serious respiratory adverse events (including respiratory failure, bronchopulmonary hemorrhage, lung infection) have been reported, although only lung infection was considered related to treosulfan. Patients with severe pulmonary impairment were excluded from the clinical study.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Long-term survival following allogeneic hematopoietic stem cell transplantation has been associated with secondary malignancies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid immunization with live vaccines; may result in severe infection or lack of vaccine response.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56526014"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Duration of neutropenia following therapy may be longer in pediatric as compared to adult patients; median duration of neutropenic period was 21 to 24 days in pediatric patients as compared to 14 to 17.5 days in adults. Consider prophylactic or empiric anti-infective treatment (eg, bacterial, viral, fungal).</p>
<p style="text-indent:0em;margin-top:2em;">Seizures have been reported in pediatric patients; one trial reported seizures in 3 patients ≤4 months of age with primary immunodeficiencies following conditioning with treosulfan (Slatter 2017); another trial reported idiopathic epilepsy in a patient 47 months of age (Morillo-Gutierrez 2020). Monitor for signs of neurological adverse reactions, including seizures; consider seizure prophylaxis (Trecondi European Medicines Agency 2019; Trecondyv Canadian product labeling 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Respiratory toxicity (grade 3/4) is more common in infants than older patients (Trecondi European Medicines Agency 2019). Hepatotoxicity is commonly observed in all age groups; associated disorientation/confusion may be more common in children and adolescents (Trecondyv Canadian product labeling 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Diaper dermatitis may occur in infants and young children due to treosulfan excretion in the urine. Frequent diaper changes are required in the 6 to 8 hours following treosulfan infusion.</p></div>
<div class="block prod-avail drugH1Div" id="F49334762"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F56621598"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F56621601"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trecondyv: 5 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F49334696"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Hematopoietic stem cell transplant: Infuse over 2 hours; administer treosulfan prior to fludarabine on the days when both medications are administered.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant. Ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, implement general extravasation management measures.</p>
<p style="text-indent:-2em;margin-left:2em;">Nausea and vomiting may commonly occur; consider prophylactic antiemetics to prevent nausea and vomiting. Mucositis prophylaxis (eg, topical antimicrobials, barrier protectants, cryotherapy, adequate oral hygiene) is recommended.</p></div>
<div class="block admp drugH1Div" id="F56526080"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Nausea and vomiting may commonly occur; consider prophylactic antiemetics to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Infuse over 2 hours. Administer prior to fludarabine on days when both medications are administered. On days treosulfan administered, use of topical creams should be avoided and diapers should be changed frequently during the 6 to 8 hours following each infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant: Ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, discontinue infusion immediately and infuse remaining portion through another vein.</p></div>
<div class="block hazard drugH1Div" id="F49352309"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Treosulfan is a cytotoxic drug (per product labeling).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F49334600"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell conditioning regimen:</b> Indicated (in combination with fludarabine) as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) at increased risk for standard conditioning therapies or pediatric patients &gt;1 year of age with AML or MDS.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for patients undergoing alloHSCT for Fanconi anemia and other DNA breakage repair disorders.</p></div>
<div class="block mst drugH1Div" id="F49334595"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Treosulfan may be confused with busulfan.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F49281720"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F49281717"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Treosulfan may increase the serum concentration of CYP2C19 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Treosulfan may increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54894258"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Males and females of reproductive potential should use effective contraception during treosulfan treatment and for 6 months after the last treosulfan dose.</p>
<p style="text-indent:0em;margin-top:2em;">Treosulfan may impair fertility. Treosulfan has been associated with ovarian suppression and amenorrhea prior to menopause. Infertility may be permanent in males; sperm cryo-conservation should be considered prior to therapy.</p>
<p style="text-indent:0em;margin-top:2em;">A long-term study followed patients for up to 12 years who received treosulfan as part of the conditioning treatment prior to allogeneic hematopoietic stem cell transplantation. Successful pregnancies and fatherhood were reported (Lazzari 2021).</p></div>
<div class="block pri drugH1Div" id="F49334601"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Use is contraindicated during pregnancy. Pregnant caregivers should avoid handling treosulfan.</p></div>
<div class="block brc drugH1Div" id="F49334602"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if treosulfan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, breastfeeding should be discontinued during treosulfan treatment.</p></div>
<div class="block mop drugH1Div" id="F49334761"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Hematopoietic stem cell transplantation: CBC with differential and platelets (daily until engraftment; frequently until hematopoietic recovery); hepatic function (transaminases, alkaline phosphatase, bilirubin; daily through post-transplant day 28); renal function (baseline). Assess cardiac function regularly. Monitor infusion site during infusion. Monitor for signs/symptoms of infection, dermatologic toxicity, pulmonary toxicity, hemorrhagic cystitis, and mucositis.</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F49334689"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Treosulfan is a bifunctional alkylating agent prodrug with cytotoxic activity in hematopoietic stem cells. Treosulfan undergoes spontaneous, pH-dependent conversion into a mono-epoxide intermediate and di-epoxybutan; the epoxides alkylate and cross-link DNA, and are considered responsible for the stem cell depleting, immune-suppressive, and antineoplastic effects.</p></div>
<div class="block phk drugH1Div" id="F49334690"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Rapidly distributed to body (with limited blood brain barrier penetration). V<sub>d</sub>: Adults: IV: 20 to 47 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted spontaneously (non-enzymatically) into the active mono-epoxide intermediate and finally to di-epoxybutan.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: IV: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: IV: At the end of the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: IV: 14% to 40% (within 24 hours) as unchanged drug.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49627000"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ovastat | Trecondi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ovastat | Trecondi | Treosulfan tillomed</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Trecondi | Treoforon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Treosulfan tillomed</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emtreo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trecondi | Treosulfan tillomed</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ovastat | Trecondi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Trecondi | Treosulfan medac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ovastat | Ovastat farma mondo | Trecondi | Treosulfan tillomed</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ovastat | Trecondi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Treosulfan medac</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ovastat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trecondi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ovastat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606445">
<a name="31606445"></a>Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematol</i>. 2020;7(1):e28-e39. doi:10.1016/S2352-3026(19)30157-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/31606445/pubmed" id="31606445" target="_blank">31606445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31701524">
<a name="31701524"></a>Chiesa R, Standing JF, Winter R, et al. Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial. <i>Clin Pharmacol Ther</i>. 2020;108(2):264-273. doi:10.1002/cpt.1715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/31701524/pubmed" id="31701524" target="_blank">31701524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32203268">
<a name="32203268"></a>Kalwak K, Mielcarek M, Patrick K, et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplant</i>. 2020;55(10):1996-2007. doi:10.1038/s41409-020-0869-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/32203268/pubmed" id="32203268" target="_blank">32203268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34568066">
<a name="34568066"></a>Lazzari L, Ruggeri A, Lupo Stanghellini MT, et al. Treosulfan-based conditioning regimen prior to allogeneic stem cell transplantation: long-term results from a phase 2 clinical trial. <i>Front Oncol</i>. 2021;11:731478. doi:10.3389/fonc.2021.731478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/34568066/pubmed" id="34568066" target="_blank">34568066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27884839">
<a name="27884839"></a>Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. <i>Blood</i>. 2016;128(3):440-448. <i>Blood</i>. 2016;128(21):2585. doi:10.1182/blood-2016-10-745455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/27884839/pubmed" id="27884839" target="_blank">27884839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332189">
<a name="33332189"></a>Peters C, Dalle JH, Locatelli F, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. <i>J Clin Oncol</i>. 2021;39(4):295-307. doi:10.1200/JCO.20.02529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/33332189/pubmed" id="33332189" target="_blank">33332189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29155317">
<a name="29155317"></a>Slatter MA, Rao K, Abd Hamid IJ, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. <i>Biol Blood Marrow Transplant</i>. 2018;24(3):529-536. doi:10.1016/j.bbmt.2017.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/treosulfan-united-states-not-available-drug-information/abstract-text/29155317/pubmed" id="29155317" target="_blank">29155317</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Trecondi (treosulfan) [summary of product characteristics]. Wedel, Germany: Medac; June 2019.</div>
</li>
<li>
<div class="reference">
                  Trecondyv (treosulfan) [product monograph]. Bolton, Ontario, Canada: Medexus Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed December 30, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134625 Version 39.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
